Advanced immunotherapy may hold promise for children with brain cancer
Posted: 16 May 2023 An advanced immunotherapy treatment could hold promise for children with an inoperable type of brain cancer, according to new research. At a glance Diffuse Intrinsic Pontine Glioma (DIPG) is an aggressive type of brain…
Innovative Peter Mac Trial to Improve Patient Recovery from Surgery
Posted: 16 May 2023 A ground-breaking trial using pharmacogenomics to improve patient recovery following surgery is now underway at Peter Mac in collaboration with the University of Adelaide, Monash University, and the University of Melbourne. The research –…
Funding boost advances research on cancer vaccine
Posted: 12 May 2023 New research that could lead to a vaccine for patients with hard-to-treat cancers has been backed with over $900,000 in funding from the Medical Research Future Fund (MRFF). The WEHI-led project aims to enhance…
Victorian Government to accelerate Bionics Institute’s new hearing test for babies, EarGenie, to commercialisation.
Posted: 12 May 2023 Bionic Institute’s novel hearing diagnostic system, EarGenie®, moves closer to commercialisation with a new government grant of over $1m The Bionics Institute’s new hearing diagnostic system for babies, EarGenie, is one step closer to…
FDA removes clinical hold on Immuron’s new campylobacter ETEC therapeutic
Posted: 12 May 2023 Immuron (ASX:IMC) has announced that the US Naval Medical Research Center has received approval from the US FDA to proceed with the clinical evaluation of the new oral therapeutic targeting campylobacter and enterotoxigenic Escherichia…
ANDHealth welcomes new $392m Industry Growth Program and $950m in funding for critical digital health infrastructure
Posted: 12 May 2023 ANDHealth has welcomed a federal budget commitment of $392m towards a new Industry Growth Program for SMEs and startups to commercialise Australian innovations aligned to the National Reconstruction Fund, and $950m in new investment…
Novel Therapies for Hard-To-Treat Diseases with Boehringer Ingelheim
Posted: 12 May 2023 Today we’re pleased to announce a new partnership with Boehringer Ingelheim! Through this partnership, Boehringer Ingelheim will leverage our natural product discovery capabilities. The goal is to accelerate their discovery and development of novel therapeutic…
Clinical trial of inhaled oxytocin to reduce maternal mortality underway in Melbourne
Posted: 12 May 2023 A Phase 1 clinical trial led by Monash University to assess the safety and performance of a novel oxytocin inhaler in healthy, non-pregnant female volunteers has commenced in Melbourne. The Inhaled Oxytocin Project, led by Professor…
ACCENT Trial Recruitment Progress
Posted: 12 May 2023 Amplia Therapeutics Limited, is pleased to announce completion of enrolment of the third cohort of patients in the ongoing Phase 1b/2a ACCENT clinical trial in frontline patients with pancreatic cancer. Amplia’s CEO and Managing…
2022 Member Survey results
Posted: 10 May 2023 On 2 December 2022, BioMelbourne Network emailed members, inviting you to complete our 2022 Member Survey which closed on 31 January 2023. We conduct this survey annually and track the trends year on year,…
Kinoxis Therapeutics partners with Boehringer Ingelheim to develop novel treatments for psychiatric patients with social dysfunction symptoms
Posted: 8 May 2023 Kinoxis Therapeutics today announced a strategic partnership and licensing agreement with Boehringer Ingelheim for the development of first-in-class oxytocin targeting precision psychiatry treatments to improve the quality of life of people living with neuropsychiatric…
More than $11M in prestigious grants awarded to researchers to combat antibiotic resistance
Posted: 8 May 2023 The World Health Organization (WHO) has continually highlighted antibiotic resistance as one of today’s most significant threats to the global community. Faced with rapidly growing antibiotic resistance, there is an urgent need to discover…
